Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
about
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantSatraplatin: leading the new generation of oral platinum agentsUpdate on options for treatment of metastatic castration-resistant prostate cancerTherapies in development for castrate-resistant prostate cancer.Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?New-generation platinum drugs in the treatment of cisplatin-resistant cancers.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors.A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancerSatraplatin: an orally available platinum analog for the treatment of cancer.New molecular targets in advanced prostate cancer.Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.Novel therapeutic strategies in development for prostate cancer.Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.Satraplatin in the treatment of hormone-refractory metastatic prostate cancerProstate cancer chemotherapy in the era of targeted therapy.Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.New-generation platinum agents for solid tumors.Emerging drugs for prostate cancer.Satraplatin for the therapy of castration-resistant prostate cancer.Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.Current treatment strategies for castration-resistant prostate cancerClinical and pharmacokinetic evaluation of satraplatin.Current and emerging treatments in the management of castration-resistant prostate cancer.Cabazitaxel for the treatment of castration-resistant prostate cancer.Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.
P2860
Q26851177-7CA9AA35-2745-40C8-81B5-479260B6C874Q28972468-2BB49B06-A479-4950-9875-FD9AAFA02B50Q33956051-138B9B07-051F-4121-879D-D8092266BACDQ34588402-658F250F-E1B9-4F88-BB4A-A3E20D3521F6Q35118358-BB3094F7-2044-4428-A493-019E0A90767DQ35945262-2818A12C-1B25-43CB-A2AB-469A9372B8FEQ36210926-28233610-910D-4103-AE35-3ED4E3AC11F2Q36272854-A39B0E7C-5481-413A-9CFA-2839A34D7BECQ36417757-575F1EFE-0454-469D-91B0-77C6F7C2F22DQ36428631-81339F6B-7586-4CE0-BAF8-FF370FEC93E0Q36532071-67AC9625-C18E-4A1A-A9FB-32CAB76C9D50Q36532080-4205F639-6D9D-4BE3-9C70-937CC6A22B03Q36861592-EF88FD4C-FD31-489B-8FDC-6DC81F5A9251Q37038977-D9E4C472-7E62-4552-92D2-5033BBB40B40Q37136248-8AA6051F-91F7-49B9-B813-833742C853B5Q37160386-B75A1059-25F1-4B1A-A0CF-4DC53D860396Q37180864-039ADF19-4797-4D1C-8763-D55CA5302951Q37255452-D9777FE4-21E1-40B3-B151-8C6FAE625B83Q37401326-C6FBB4C4-5EB6-45DE-969F-B7ED09B3D451Q37570555-8B08E290-0FA2-4A3D-A479-0BA2DFEC1296Q37605845-634368E3-7E2D-4045-B638-A5E9AA933110Q37845245-A607CE8E-523B-4281-B247-817EF63771B7Q37860950-CBA6A5E8-E1E9-490E-8D15-63FBC558C17AQ37958009-60C5FE33-A42A-4FD6-8E3C-06041CA0D05FQ38030595-D2351B43-7B13-4DDB-BB37-298E32F549D1Q38861952-6BECA87A-5C31-44BE-8D61-1B97C9F81246Q39018004-FBCF07AC-59B7-4249-BEE8-D9A5CB02996BQ40064331-F3425196-BE75-471B-B902-BBFFEF187860
P2860
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@ast
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@en
type
label
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@ast
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@en
prefLabel
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@ast
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@en
P2093
P1476
Phase II study of oral bis (ac ...... actory prostate cancer (HRPC).
@en
P2093
Cindy Connell
David Lebwohl
David Peereboom
David Vaughn
Laura Wood
Tahir Latif
P356
10.1023/B:DRUG.0000047109.76766.84
P577
2005-01-01T00:00:00Z
P6179
1043891763